Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00834171 · ClinicalTrials.gov registry record
A Retrospective Evaluation of the Intraocular Pressure Spikes With Loteprednol and Loteprednol/Tobramycin
A clinical trial, sponsored by Allergan.
- Completed
- Registry status
- 50
- Enrollment target
NCT00834171 is a clinical trial that has completed, run by Allergan. The registered enrollment target is 50 participants.
The verdict
NCT00834171 has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- 50 participants
- Enrollment target
Study Summary
Patient charts will be reviewed to evaluate the incidence of intraocular pressure spikes while on Loteprednol etabonate ophthalmic suspension 0.5%, Loteprednol etabonate (0.5%) and tobramycin (0.3%)
Interventions
- DRUG Loteprednol etabonate ophthalmic suspension 0.5%
- DRUG Loteprednol etabonate (0.5%) and tobramycin (0.3%).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2009-01 |
| Est. Completion | 2009-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00834171
The ClinicalTrials.gov registry entry for NCT00834171 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Loteprednol etabonate ophthalmic suspension 0.5% is the first listed.
NCT00834171 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00834171 about?
NCT00834171 is a clinical study titled "A Retrospective Evaluation of the Intraocular Pressure Spikes With Loteprednol and Loteprednol/Tobramycin". Patient charts will be reviewed to evaluate the incidence of intraocular pressure spikes while on Loteprednol etabonate ophthalmic suspension 0.5%, Loteprednol etabonate (0.5%) and tobramycin (0.3%)
What is the current status of trial NCT00834171?
This trial is currently completed. The enrollment target is 50 participants. The study started on 2009-01. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00834171?
The interventions under investigation include: Loteprednol etabonate ophthalmic suspension 0.5% (DRUG), Loteprednol etabonate (0.5%) and tobramycin (0.3%). (DRUG).
Who is sponsoring clinical trial NCT00834171?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.